Karen E. Keller

Elana Araj

David M. Fry

Nathan R. Hoeschen

Giancarlo L. Scaccia

Jack B. Blumenfeld

F. Dominic Cerrito

Kevin S. Prussia

Lisa J. Pirozzolo

Evangeline Shih

Gabriel P. Brier

Anastasia M. Fernands

Eric C. Stops

Emily R. Whelan

Timothy A. Cook

Anthony D. Raucci

Katherine P. Kieckhafer

Jonathan A. Cox

Colleen A. Superko

Michelle E. Irwin

Deric Geng

Gillian T. Farrell

Teva's ANDA filing for generic AURYXIA® sparks Keryx lawsuit over 12 patents, citing a unique "intrinsic dissolution rate" for kidney disease treatment.

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

Name	Ratings
Keryx Biopharmaceuticals Inc	-- -- --
Panion BF Biotech Inc	-- -- --

Name	Ratings
Morris Nichols Arsht & Tunnell LLPLocal	L5 A
Jack B. Blumenfeld	L5 A
Anthony D. Raucci	L2 B
Wilmer Cutler Pickering Hale Dorr LLP	L5 A
Lisa J. Pirozzolo	L5 A
Emily R. Whelan	L2 A
Timothy A. Cook	L2 A
Kevin S. Prussia	L2 D
Katherine P. Kieckhafer	-- -- --
Jonathan A. Cox	-- -- --
Colleen A. Superko	-- -- --
Deric Geng	-- -- --
Gillian T. Farrell	-- -- --
Quinn Emanuel Urquhart & Sullivan LLP	L5 A
F. Dominic Cerrito	L5 A
Eric C. Stops	L5 D
Evangeline Shih	L4 B
Anastasia M. Fernands	L3 B
Gabriel P. Brier	L3 D
Michelle E. Irwin	-- -- --

Name	Ratings
Teva Pharmaceuticals USA Inc	L5 E
Teva Pharmaceutical Industries Ltd	L5 E

Name	Ratings
Greenberg Traurig LLP	L5 E
Elana Araj	L3 E
Giancarlo L. Scaccia	L2 D
Shaw Keller LLPLocal	L4 D
Karen E. Keller	L4 E
Nathan R. Hoeschen	L3 B
David M. Fry	L3 E

1:18-cv-02012

Keryx Biopharma Inc v. Teva Pharma USA Inc